Valneva CMO Juan Carlos Jaramillo

Covid-19 roundup: Val­ne­va de­fends vac­cine in wake of un­flat­ter­ing boost­er study; Mer­ck goes af­ter Pfiz­er’s new an­tivi­ral — re­port

Falling way be­hind the fron­trun­ners in de­liv­er­ing a Covid-19 vac­cine, French biotech Val­ne­va has placed high hopes on boost­ers.

Which may be why it is re­act­ing strong­ly to a study sug­gest­ing that its can­di­date, VLA2001, was the on­ly one out of sev­en that didn’t work well as a boost­er for vol­un­teers who had dos­es of the Pfiz­er/BioN­Tech mR­NA shot.

The com­pa­ny is try­ing to fire back Mon­day morn­ing, days af­ter re­sults from the COV-Boost study were pub­lished in The Lancet.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.